Investors / United Kingdom / LifeArc Ventures
LifeArc Ventures
Corporate VC · London, United Kingdom · Europe
LifeArc Ventures is the venture arm of LifeArc, a self-funded medical research charity that turns promising science into patient impact. It invests in and supports life science companies, offering funding alongside scientific and translational advice from LifeArc's scientists and laboratories.
Invests inHealthcare & Biotech
In its own wordstherapeuticsmedtechhealthtechlife sciencestranslational sciencerare diseases
Your fit with LifeArc Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsLifeArc Ventures lists 18 checked portfolio companies on its own site and is named in 5 funding rounds. Its most frequent entry is Series A, 60% of the companies with a known first round. Its largest themes are Healthcare & Biotech (95%) and Consumer (5%). 58% of its companies are based in United Kingdom. It invests most often alongside Modi Ventures, ARTIS and Accelerate Fund.
Counts come from funding rounds that name LifeArc Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not LifeArc Ventures' whole history. Rounds on record name 5 companies; its own site lists 18. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 60% |
| Series B | 40% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 4 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 46th | 18 companies |
| Recent activity | 82th | 4 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 96th | 28% of companies confirmed by a round |
| Sector focus | 97th | 95% in its largest sector |
| Reach | 58th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Modi Ventures | 3 |
| ARTIS | 2 |
| Accelerate Fund | 2 |
| Advent Life Sciences | 2 |
| Fountain Healthcare Partners | 2 |
| Frazier Life Sciences | 2 |
| Future Planet Capital | 2 |
| Monograph Capital | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers18100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 95% | 15% |
| Consumer | 5% | 3% |
Co-investor network
who it backs companies with, and who they back togetherCompare LifeArc Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with LifeArc Ventures| Date | Company | Stage |
|---|---|---|
| 29 Oct 2026 | Series B | |
| 24 Jun 2026 | Series A | |
| 5 May 2026 | Series A | |
| 20 Jan 2026 | Series B | |
| 17 Mar 2025 | Series A |
Round details for LifeArc Ventures
Amounts, full round histories and every co-investor in LifeArc Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
18 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Affect Therapeutics provides mental health and addiction treatment services. | Healthcare & Biotech | Portfolio page | ||
| AviadoBio develops gene therapies for neurodegenerative diseases | Healthcare & Biotech | Portfolio page | ||
| Climb Bio develops differentiated monoclonal antibodies for immune-mediated diseases. | Healthcare & Biotech | Portfolio page | ||
| Corteria Pharmaceuticals is a privately held company developing first-in-class drugs for indications of high unmet medical need, such as obesity, heart failure subpopulations and autosomal dominant polycystic kidney disease | Healthcare & Biotech | Portfolio page | ||
| Cumulus Neuroscience develops and provides a platform for assessing novel CNS therapies with real-world objective data | Healthcare & Biotech | Portfolio page | ||
| Cytospire Therapeutics develops next generation immune cell engagers, including multispecific antibodies and gamma delta T cell engagers, for cancer therapies. | Healthcare & Biotech | May 2026Series A | Page + round | |
| Exciva is developing a groundbreaking therapy that effectively and safely addresses neuropsychiatric symptoms including agitation in patients with Alzheimer’s disease dementia. | Healthcare & Biotech | Jan 2026Series B | Page + round | |
| Fluid Biomed is advancing the first-of-its-kind polymer-based flow-diverting stent through clinical investigation to treat brain aneurysms. | Healthcare & Biotech | Portfolio page | ||
| GlycoEra develops biologics to selectively target and degrade specific circulating proteins that drive diseases such as autoantibodies in immune-driven disorders | Healthcare & Biotech | Portfolio page | ||
| Hillstar Bio is developing precision immunotherapies for autoimmune diseases by selectively targeting and depleting pathogenic immune cells | Healthcare & Biotech | Portfolio page | ||
| Ikarovec is advancing a pipeline of next generation gene therapies to treat major chronic eye diseases. | Healthcare & Biotech | Portfolio page | ||
| Maxion Therapeutics creates protein therapeutics for treating diseases using its KnotBody technology | Healthcare & Biotech | Mar 2025Series A | Page + round | |
| MC Sciences develops therapeutics targeting mast cells in various disease areas, including immunology, dermatology, and respiratory disorders. | Healthcare & Biotech | Portfolio page | ||
| The company designs and sells earbuds for improving sleep. | Healthcare & BiotechConsumer | Oct 2026Series B | Page + round | |
| Pheno Therapeutics is a clinical stage biotech company developing GPR17 antagonists for neurodegenerative and demyelinating disorders | Healthcare & Biotech | Portfolio page | ||
| RQ Bio discovers and develops long-acting monoclonal antibodies against seasonal influenza | Healthcare & Biotech | Jun 2026Series A | Page + round | |
| T-Cypher Bio develops drugs against novel disease-specific targets to improve the lives of patients with cancer and autoimmune diseases. | Healthcare & Biotech | Portfolio page | ||
| Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- lifearcventures.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 17 Mar 2025
- Companies checked
- 18
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get LifeArc Ventures' profile as data
Pull LifeArc Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/lifearcventures.com
# also
GET /v1/firms/lifearcventures.com/portfolio
GET /v1/firms/lifearcventures.com/coinvestors
GET /v1/firms/lifearcventures.com/news